Image: Getty Images
Three HMS teams are part of $65 million federal program to make genome-editing technologies safer
Three teams of Harvard Medical School researchers are launching projects to support responsible innovation in gene editing and to protect against threats to genome integrity. The initiative is part of a new program overseen by the Defense Advanced Research Projects Agency (DARPA), the research arm of the U.S. Department of Defense.
Announced on July 19, the Safe Genes program aims to establish a fundamental understanding of how gene-editing technologies function; devise means to safely, responsibly and predictably harness them for beneficial ends; and address potential health and security concerns related to their accidental or intentional misuse.
DARPA plans to invest $65 million in Safe Genes during the next four years.
Gene-editing technologies have captured increasing attention in recent years for their numerous potential applications, including allowing researchers to selectively disable cancerous cells in the body, control the viability of populations of disease-spreading mosquitoes or enable native flora and fauna to defend themselves against invasive species.
The potential national security applications and implications of these technologies are equally profound, including helping to protect military troops against infectious disease, mitigate threats posed by irresponsible or nefarious use of biological technologies and enhance the development of new resources derived from synthetic biology, such as novel chemicals, materials and coatings with useful, unusual properties.
The Safe Genes program supports a total of seven teams that will work to collect data and develop tools to support bioinnovation and combat biothreats. The three HMS research groups and their leaders are:
A team led George Church, the Robert Winthrop Professor of Genetics at HMS, seeks to develop systems to safeguard genomes by detecting, preventing and ultimately reversing mutations that may arise from exposure to radiation. The team’s work will involve the creation of novel computational and molecular tools to enable the development of precise editors that can distinguish between nearly identical genetic sequences. The team also plans to screen natural and synthetic drugs to determine how effectively they inhibit gene-editing activity.
Amit Choudhary, HMS assistant professor of medicine at Brigham and Women’s Hospital, leads a team that is developing tools that can switch genome editing on and off in bacteria, mammals and insects, including control of gene drives in a mosquito malaria vector, Anopheles stephensi. The team seeks to build a general platform for the rapid and cost-effective identification of chemicals that will block contemporary and next-generation genome editors. Such chemicals could propel the development of therapeutic applications of genome editors by limiting off-target effects, or they could protect against future biological threats. The team will also construct synthetic genome editors for precision genome engineering.
Keith Joung, HMS professor of pathology at Massachusetts General Hospital, heads a team that aims to develop novel, highly sensitive methods to control and measure on-target genome-editing activity—and to limit and measure off-target activity—and to apply these methods to regulate the activity of mosquito gene-drive systems over multiple generations. The team will also develop novel strategies to achieve control over genome editors, including drug-regulated versions of these molecules. The team will take advantage of contained facilities that simulate natural environments to study how drive systems perform in mosquitoes under conditions approximating the natural world.
Additional Safe Genes teams are based at MIT, North Carolina State University, the University of California, Berkeley, and the University of California, Riverside.
Driving the future
Achieving the ambitious goals set by the Safe Genes program will require more complete knowledge about how gene editors and derivative technologies including gene drives, function at different physical and temporal scales under different environmental conditions across multiple generations of an organism.
In parallel, demonstrating the ability to precisely control gene edits, turning them on and off under certain conditions or even reversing their effects entirely, will be paramount to translating these tools to practical applications.
By establishing empirical foundations and removing lingering unknowns through laboratory-based demonstrations, the Safe Genes teams will work to substantially minimize the risks inherent in such powerful tools.
During the course of the program, teams will engage with potential stakeholders, including government regulators, to increase the value of the science and to shape experiments around their questions and concerns. Additionally, as an aid to policymakers, the teams will establish models for incorporating stakeholder engagement in future decisions on whether and how to apply such tools.
The teams intend to refine their research over the course of the program by building initial mathematical models of gene-editing systems, testing them in insect and animal models to validate hypotheses and feeding the results back into the simulations to fine-tune parameters.
Teams will also incorporate insights garnered from engagement with regulators and, in some cases, from local communities considering gene-editing applications. Teams may run additional experiments to collect data that address concerns and could inform future regulatory reviews.
“The field of gene editing has been advancing at an astounding pace, opening the door to previously impossible genetic solutions but without much emphasis on how to mitigate potential downsides,” said Renee Wegrzyn, the Safe Genes program manager. “DARPA launched Safe Genes to begin to refine those capabilities by emphasizing safety first for the full range of potential applications, enabling responsible science to proceed by providing tools to prevent and mitigate misuse.”
Adapted from a DARPA news release.
source: Harvard University – Harvard Medical School